These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19884563)

  • 1. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
    Tian J; Shidyak A; Periyasamy SM; Haller S; Taleb M; El-Okdi N; Elkareh J; Gupta S; Gohara S; Fedorova OV; Cooper CJ; Xie Z; Malhotra D; Bagrov AY; Shapiro JI
    Hypertension; 2009 Dec; 54(6):1313-20. PubMed ID: 19884563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy.
    Elkareh J; Kennedy DJ; Yashaswi B; Vetteth S; Shidyak A; Kim EG; Smaili S; Periyasamy SM; Hariri IM; Fedorova L; Liu J; Wu L; Kahaleh MB; Xie Z; Malhotra D; Fedorova OV; Kashkin VA; Bagrov AY; Shapiro JI
    Hypertension; 2007 Jan; 49(1):215-24. PubMed ID: 17145984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy.
    Elkareh J; Periyasamy SM; Shidyak A; Vetteth S; Schroeder J; Raju V; Hariri IM; El-Okdi N; Gupta S; Fedorova L; Liu J; Fedorova OV; Kahaleh MB; Xie Z; Malhotra D; Watson DK; Bagrov AY; Shapiro JI
    Am J Physiol Renal Physiol; 2009 May; 296(5):F1219-26. PubMed ID: 19261738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
    Fedorova OV; Emelianov IV; Bagrov KA; Grigorova YN; Wei W; Juhasz O; Frolova EV; Marshall CA; Lakatta EG; Konradi AO; Bagrov AY
    J Hypertens; 2015 Aug; 33(8):1602-10. PubMed ID: 26136067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.
    Haller ST; Yan Y; Drummond CA; Xie J; Tian J; Kennedy DJ; Shilova VY; Xie Z; Liu J; Cooper CJ; Malhotra D; Shapiro JI; Fedorova OV; Bagrov AY
    J Am Heart Assoc; 2016 Sep; 5(10):. PubMed ID: 27694325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy.
    Kennedy DJ; Vetteth S; Periyasamy SM; Kanj M; Fedorova L; Khouri S; Kahaleh MB; Xie Z; Malhotra D; Kolodkin NI; Lakatta EG; Fedorova OV; Bagrov AY; Shapiro JI
    Hypertension; 2006 Mar; 47(3):488-95. PubMed ID: 16446397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in the development of uremic cardiomyopathy following partial nephrectomy: Role of progesterone.
    Drummond CA; Buddny G; Haller ST; Liu J; Yan Y; Xie Z; Malhotra D; Shapiro JI; Tian J
    J Hypertens (Los Angel); 2013 Jan; 2():. PubMed ID: 24404431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure.
    Cittadini A; Casaburi C; Monti MG; Di Gianni A; Serpico R; Scherillo G; Saldamarco L; Vanasia M; Saccà L
    Cardiovasc Drugs Ther; 2002 May; 16(3):195-201. PubMed ID: 12374896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
    Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
    Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts.
    Drummond CA; Hill MC; Shi H; Fan X; Xie JX; Haller ST; Kennedy DJ; Liu J; Garrett MR; Xie Z; Cooper CJ; Shapiro JI; Tian J
    Physiol Genomics; 2016 Mar; 48(3):220-9. PubMed ID: 26702050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canrenone Restores Vasorelaxation Impaired by Marinobufagenin in Human Preeclampsia.
    Agalakova NI; Grigorova YN; Ershov IA; Reznik VA; Mikhailova EV; Nadei OV; Samuilovskaya L; Romanova LA; Adair CD; Romanova IV; Bagrov AY
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cardiotonic steroids on dermal collagen synthesis and wound healing.
    El-Okdi N; Smaili S; Raju V; Shidyak A; Gupta S; Fedorova L; Elkareh J; Periyasamy S; Shapiro AP; Kahaleh MB; Malhotra D; Xie Z; Chin KV; Shapiro JI
    J Appl Physiol (1985); 2008 Jul; 105(1):30-6. PubMed ID: 18483172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse.
    Kennedy DJ; Elkareh J; Shidyak A; Shapiro AP; Smaili S; Mutgi K; Gupta S; Tian J; Morgan E; Khouri S; Cooper CJ; Periyasamy SM; Xie Z; Malhotra D; Fedorova OV; Bagrov AY; Shapiro JI
    Am J Physiol Renal Physiol; 2008 Feb; 294(2):F450-4. PubMed ID: 18032546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate.
    Sorrentino R; Cirino G; Calignano A; Mancuso F; Sorrentino L; Andriuoli G; Pinto A
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):519-25. PubMed ID: 8891876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone.
    Kashkin VA; Shekunova EV; Egorov AY; Bagrov AY
    Curr Hypertens Rev; 2018; 14(1):35-38. PubMed ID: 29437012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
    Dasgupta A; Saffer H; Wells A; Datta P
    J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of canrenone on aorta and right ventricle of the rat.
    Cargnelli G; Trevisi L; Debetto P; Luciani S; Bova S
    J Cardiovasc Pharmacol; 2001 May; 37(5):540-7. PubMed ID: 11336105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation.
    Klimanova EA; Petrushanko IY; Mitkevich VA; Anashkina AA; Orlov SN; Makarov AA; Lopina OD
    FEBS Lett; 2015 Sep; 589(19 Pt B):2668-74. PubMed ID: 26297827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.